Michel Faure, Ph.D. (Founder, President, and CEO)
Dr. Faure received his Ph.D. in Molecular Biology from Université Paris-Sud, Orsay (France) and then embarked on a postdoc at Columbia University. He took a position at the CNRS in France and then returned to the US for a second postdoc at UCSF. There, Dr. Faure worked in Professor Henry Bourne's lab, where he made several key contributions to the understanding of the cross-talk between GPCRs and the MAPK pathway. He then joined SUGEN, a pioneer in the field of kinase inhibitors, where he led several early drug discovery projects in oncology. He later joined Chiron/Novartis in Emeryville, where his responsibilities included defining and implementing biomarker and patient stratification strategies for oncology drug discovery projects. He also managed several outside collaborations, including the procurement and validation of tool antibodies.
Dr. Faure brings more than twenty years of biopharmaceutical research experience in oncology drug discovery. He founded Ensigna Biosystems, Inc. in March 2014 because he understands how the most advanced molecular pathology techniques are essential to the development of targeted therapies and the implementation of personalized medicine.
Majid Ghoddusi, D.V.M., Ph.D. (Co-founder and Vice President)
Dr. Ghoddusi received his Doctorate of Veterinary Medicine from Urmia University in Iran. He then moved to Australia where he completed his Postgraduate Diploma and his Ph.D. in Pathology at the University of Queensland. He worked as postdoctoral research investigator at the Australian National University and Children’s Medical Research Institute. In the US, Dr. Ghoddusi was staff pathologist for the diagnostic laboratory at UC Davis before accepting a toxicologic pathologist and study director role in the GLP-compliant contract research field in Silicon Valley. Recently, Dr. Ghoddusi led the Experimental Pathology group at Novartis in Emeryville, where he supported the entire oncology portfolio, spanning early target validation, in vivo model characterization, pharmacodynamics and efficacy evaluation, toxicologic histopathology and patient stratification.
Dr. Ghoddusi is the co-founder of Ensigna Biosystems, Inc. He brings with him a broad spectrum of pathology expertise in drug discovery, pre-clinical toxicologic pathology and molecular pathology. He is a member of the Society of Toxicologic Pathology, a member of the Society for Investigative Pathology, and a member of the advisory panel of PathXL, Inc., a digital pathology company.
Yu-Chien Chou, Ph.D. (Director of Operations)
Dr. Chou has over 15 years of hands-on research experience in preclinical pharmacology, translational oncology and biomarker strategies for therapeutic drug discovery. Prior to joining Ensigna Biosystems, she led teams at Exelixis responsible for in vivo characterization of developmental compounds for numerous oncology and metabolic disease programs. She also worked as an oncology scientist in Experimental Pathology/Translational Sciences at Novartis. She has held positions at the Lawrence Berkeley National Laboratory and UC Berkeley, making significant contributions to the understanding of mammary carcinogenesis. Her sphere of expertise includes PK/PD/efficacy, tissue-based biomarker analysis supporting lead optimization, translational research and IND filings, immunohistochemistry and antibody validation. Dr. Chou received her Ph.D. (Endocrinology and Cancer Biology) from UC Berkeley and a BS degree (Biology) from Yokohama City University, Japan. She is fluent in English, Japanese and Mandarin.
In her current role as Director of Operations, Dr. Chou is managing our molecular pathology facility and building our histology team using automated immunohistochemistry technologies to aid in antibody validation and biomarker strategy.